203 related articles for article (PubMed ID: 20066473)
21. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
[TBL] [Abstract][Full Text] [Related]
22. Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells.
Kim MH; Jeong YJ; Cho HJ; Hoe HS; Park KK; Park YY; Choi YH; Kim CH; Chang HW; Park YJ; Chung IK; Chang YC
Oncol Rep; 2017 Feb; 37(2):777-784. PubMed ID: 27959445
[TBL] [Abstract][Full Text] [Related]
23. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
24. Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.
Choijamts B; Naganuma Y; Nakajima K; Kawarabayashi T; Miyamoto S; Tachibana K; Emoto M
Cancer Sci; 2011 Feb; 102(2):452-9. PubMed ID: 21205068
[TBL] [Abstract][Full Text] [Related]
25. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Nodal suppresses angiogenesis and growth of human gliomas.
Hueng DY; Lin GJ; Huang SH; Liu LW; Ju DT; Chen YW; Sytwu HK; Chang C; Huang SM; Yeh YS; Lee HM; Ma HI
J Neurooncol; 2011 Aug; 104(1):21-31. PubMed ID: 21116837
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
28. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis in gliomas: biology and molecular pathophysiology.
Fischer I; Gagner JP; Law M; Newcomb EW; Zagzag D
Brain Pathol; 2005 Oct; 15(4):297-310. PubMed ID: 16389942
[TBL] [Abstract][Full Text] [Related]
30. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Friedman HS; Keir ST; Houghton PJ
Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
[TBL] [Abstract][Full Text] [Related]
31. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.
Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H
Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
de Groot JF; Yung WK
Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
34. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
[TBL] [Abstract][Full Text] [Related]
35. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Lin CJ; Lin YL; Luh F; Yen Y; Chen RM
Oncotarget; 2016 Jul; 7(27):42408-42421. PubMed ID: 27285755
[TBL] [Abstract][Full Text] [Related]
36. Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting.
Hamans B; Navis AC; Wright A; Wesseling P; Heerschap A; Leenders W
Neuro Oncol; 2013 Dec; 15(12):1615-24. PubMed ID: 24158109
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
[TBL] [Abstract][Full Text] [Related]
39. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
